A fully 3D-printed versatile tumor-on-a-chip allows multi-drug screening and correlation with clinical outcomes for personalized medicine

Eliana Steinberg, Roy Friedman, Yoel Goldstein, Nethanel Friedman, Ofer Beharier, Jonathan Abraham Demma, Gideon Zamir, Ayala Hubert, Ofra Benny*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Optimal clinical outcomes in cancer treatments could be achieved through the development of reliable, precise ex vivo tumor models that function as drug screening platforms for patient-targeted therapies. Microfluidic tumor-on-chip technology is emerging as a preferred tool since it enables the complex set-ups and recapitulation of the physiologically relevant physical microenvironment of tumors. In order to overcome the common hindrances encountered while using this technology, a fully 3D-printed device was developed that sustains patient-derived multicellular spheroids long enough to conduct multiple drug screening tests. This tool is both cost effective and possesses four necessary characteristics of effective microfluidic devices: transparency, biocompatibility, versatility, and sample accessibility. Compelling correlations which demonstrate a clinical proof of concept were found after testing and comparing different chemotherapies on tumor spheroids, derived from ten patients, to their clinical outcomes. This platform offers a potential solution for personalized medicine by functioning as a predictive drug-performance tool.

Original languageAmerican English
Article number1157
JournalCommunications Biology
Volume6
Issue number1
DOIs
StatePublished - 13 Nov 2023

Bibliographical note

Publisher Copyright:
© 2023, The Author(s).

Fingerprint

Dive into the research topics of 'A fully 3D-printed versatile tumor-on-a-chip allows multi-drug screening and correlation with clinical outcomes for personalized medicine'. Together they form a unique fingerprint.

Cite this